TechValidate Research on TriSalus™ Life Sciences

These pages present data that TechValidate has sourced via direct research with verified customers and users of TriSalus™ Life Sciences. TechValidate stands behind the authenticity of all published data. Learn more »



11 Published TechFacts

1 Published Chart



Selected Research Highlights


TriSalus™ Life Sciences Customer Statistic

With SIS, 91% of surveyed organizations sought to overcome challenges around improving treatment response rate.

91%

TriSalus™ Life Sciences Customer Research

What is the primary clinical benefit of SIS?

What is the primary clinical benefit of SIS?

Improved Tumor Response
45%
Improved Therapy Uptake
36%
Improved Patient Outcomes
18%

TriSalus™ Life Sciences Customer Statistic

91% of organizations agreed with the following statement:

“Locoregional Pressure-Enable Drug Delivery (PEDD) of standard-of-care chemotherapy and immunotherapy limits systemic toxicity and reduces treatment side-effects vs. systemic delivery.”



More to Explore



About TriSalus™ Life Sciences

Our commitment to improving outcomes in cancer care is renewed as TriSalus Life Sciences. TriSalus develops infusion technology that helps physicians deliver therapy deeper into solid tumors while protecting healthy tissues, giving patients greater confidence in their cancer care.

TriSalus™ Life Sciences Website   TriSalus™ Life Sciences Website